- Home
- WRLD vs KROS Comparison
WRLD vs KROS Comparison
Compare WRLD & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRLD
- KROS
- Stock Information
- Founded
- WRLD 1962
- KROS 2015
- Country
- WRLD United States
- KROS United States
- Employees
- WRLD N/A
- KROS N/A
- Industry
- WRLD Finance: Consumer Services
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- WRLD Finance
- KROS Health Care
- Exchange
- WRLD Nasdaq
- KROS Nasdaq
- Market Cap
- WRLD 683.3M
- KROS 565.0M
- IPO Year
- WRLD 1991
- KROS 2020
- Fundamental
- Price
- WRLD $135.83
- KROS $16.83
- Analyst Decision
- WRLD
- KROS Buy
- Analyst Count
- WRLD 0
- KROS 14
- Target Price
- WRLD N/A
- KROS $20.67
- AVG Volume (30 Days)
- WRLD 63.4K
- KROS 1.4M
- Earning Date
- WRLD 10-23-2025
- KROS 11-05-2025
- Dividend Yield
- WRLD N/A
- KROS N/A
- EPS Growth
- WRLD N/A
- KROS N/A
- EPS
- WRLD 10.75
- KROS 1.57
- Revenue
- WRLD $570,762,378.00
- KROS $246,718,000.00
- Revenue This Year
- WRLD $0.89
- KROS $6,657.47
- Revenue Next Year
- WRLD $3.51
- KROS N/A
- P/E Ratio
- WRLD $12.42
- KROS $10.82
- Revenue Growth
- WRLD 2.33
- KROS 37798.31
- 52 Week Low
- WRLD $104.99
- KROS $9.12
- 52 Week High
- WRLD $185.48
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- WRLD 37.71
- KROS 66.50
- Support Level
- WRLD $119.01
- KROS $14.86
- Resistance Level
- WRLD $137.36
- KROS $17.30
- Average True Range (ATR)
- WRLD 8.55
- KROS 0.60
- MACD
- WRLD -0.31
- KROS 0.21
- Stochastic Oscillator
- WRLD 31.02
- KROS 82.42
About WRLD World Acceptance Corporation
World Acceptance Corp operates a small-loan consumer finance business. The company offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. It also offers income tax return preparation services to its loan customers and other individuals. The Company operates 1,024 branches in Alabama, Georgia, Idaho, Illinois, Indiana, Kentucky, Louisiana, Mississippi, Missouri, New Mexico, Oklahoma, South Carolina, Texas, Tennessee, Utah, and Wisconsin.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.